Compliance center

Controls that make science investable.

Institutional capital does not price technology alone — it prices the control environment around it. Below is ours, domain by domain.

Domains

Six control domains under continuous review.

Anti-bribery, third-party integrity and contractual controls across every transaction.

Independent review of protocols, endpoints and claims before any asset is published.

Data provenance, authorship rules and misconduct procedures aligned to global standards.

Ethics approvals, biosafety, clinical governance and regulatory correspondence.

Lawful basis, minimisation, encryption and access governance for sensitive datasets.

Quality management, information security and risk frameworks embedded in operations.

Technical, legal and IP diligence packages prepared before any capital conversation.

Every document access, NDA and approval is timestamped and attributable.

Risk matrix

Risk	Likelihood	Impact	Mitigation
Regulatory delay	3/5	4/5	Pre-submission meetings and parallel jurisdictions.
IP challenge	2/5	5/5	Freedom-to-operate opinions and layered filings.
Scale-up variance	3/5	3/5	Pilot-line validation before industrial transfer.
Data privacy exposure	2/5	4/5	De-identification and LGPD-aligned processing.
Partner dependency	2/5	3/5	Dual-source manufacturing and transfer packages.
Tax benefit disallowance	2/5	4/5	Independent technical review and defence dossier.